[1]艾儒棣,方明,谭强,等.汉唐宋时期中医文献对破伤风的认识及贡献[J].中医杂志, 2011, 52(16):1437-1438.
[2]Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1260-1344.
[3]Maternal and Neonatal Tetanus(MNT)elimination:the initiative and challenges[EB/OL].http://www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/.
[4]Finkelstein P, Teisch L,Allen CJ, et al. Tetanus:a potential public health threat in times of disaster[J]. Prehosp Disaster Med, 2017, 32(3):339-342.
[5]Tetanus: Causes and Transmission[EB/OL]. http://www.cdc.gov/tetanus/about/causes-transmission.html.
[6]Thwaites CL, Yen LM, Nga NT, et al. Impact of improved vaccination programme and intensive care facilities on incidence and outcome of tetanus in southern Vietnam, 1993-2002[J]. Trans R Soc Trop Med Hyg, 2004, 98(11):671-677.
[7]中国疾病预防控制中心.新生儿破伤风知识天地[EB/OL]. http://www.chinacdc.cn/jkzt/crb/xsepsf/zstd/200509/t20050907_24856.htm
[8]Calvo AC, Olivo AC, Manzano R, et al. Fragment C of tetanus toxin:new insights into its neuronal signaling pathway[J]. Int J Mol Sci, 2012, 13(6):6883-6901.
[9]Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins[J]. Molecular Microbiology, 1994, 13(1):1.
[10]Fishman PS, Carrigan DR. Motoneuron uptake from the circulation of the binding fragment of tetanus toxin[J]. Arch Neurol, 1988, 45(5):558-561.
[11]Salinas S, Schiavo G, Kremer EJ. A hitchhiker’s guide to the nervous system: the complex journey of viruses and toxins[J]. Nat Rev Microbiol, 2010, 8(9):645-655.
[12]Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin[J]. Nature, 1992, 359(6398):832-835.
[13]Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis[J]. Physiol Rev, 2000, 80(2):717-766.
[14]Tetanus: information for health professionals[EB/OL]. https://www.gov.uk/government/publications/tetanus-advice-for-health-professionals (Effective date 30th June 2015).
[15]Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus[J]. Lancet, 2015, 385(9965):362-370.
[16]Tetanus vaccines: WHO position paper-February 2017[J]. Wkly Epidemiol Rec, 2017, 92(6):53-76.
[17]吴孟超,吴在德.黄家驷外科学(第7版)[M].北京:人民卫生出版社, 2008:127-128.
[18]陈孝平,汪建平,赵继宗.外科学(第9版)[M].北京:人民卫生出版社, 2018:117-119.
[19]Millard AH. Local Tetanus[J]. The Lancet, 1954, 264(6843):844-846.
[20]Cook TM, Protheroe RT, Handel JM.Handel. Tetanus:a review of literature[J]. British J Anaesth, 2001, 87(3):477-487.
[21]Kotani Y, Kubo K, Otsu S, et al. Cephalic tetanus as a differential diagnosis of facial nerve palsy[J].BMJ Case Rep, 2017, 20:2017.
[22]Ataro P, Mushatt D, Ahsan S. Tetanus: a review[J]. South Med J, 2011, 104(8):613-617.
[23]Japanese Society of Chemotherapy Committee on guidelines for treatment of anaerobic infections,Japanese Association for Anaerobic Infection Research.Chapter 2-12-4, Anaerobic infections(individual fields):tetanus[J]. J Infect Chemother, 2011, 17 (1):125-132.
[24]Abrahamian FM, Pollack CJ, LoVecchio F, et al. Fatal tetanus in a drug abuser with “protective” antitetanus antibodies[J]. J Emerg Med, 2000, 18(2):189-193.
[25]Vollman KE, Acquisto NM, Bodkin RP.A case of tetanus infection in an adult with a protective tetanus antibody level[J]. Am J Emerg Med, 2014, 32(4):392.
[26]Diphtheria, tetanus, and pertussis: recommendation for vaccine use and other preventive measures.Recommendation of the Immunization Practices Advisory committee(ACIP)[J]. MMWR Recomm Rep, 1991, 40(RR-10):1-28.
[27]The immunological basis for immunization series module 3:tetanus.Update 2018[EB/OL].World Health Organization, Geneva, 2018. Available at http://www.who.int/immunization/documents/ISBN9789241513616/en/.accessed on October 2018.
[28]崔健,曹雷,郑景山,等.中国2015年国家免疫规划疫苗报告接种率分析[J].中国疫苗和免疫, 2017, 23(6):601-607.
[29]徐鹭,丁筱竹,路坚. 南京市25 岁以下健康人群白喉和破伤风抗体水平调查[J]. 现代预防医学, 2010, 37(16): 3155-3156.
[30]Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 2018, 67(2):1-44.
[31]周海云.人破伤风免疫球蛋白及其应用[J].微生物免疫学进展, 2006, 34(2):84-86.
[32]余超, 徐玉茗, 徐瑾,等. 破伤风抗毒素致不良反应2636例文献分析[J]. 中国药房, 2017, 36:5072-5075.
[33]何庆,丛鲁红. 破伤风免疫球蛋白在破伤风治疗中的应用[J].中国生物制品学杂志, 2007, 20(5):391-392.
[34]丁天然,张永信.马破伤风免疫球蛋白F(ab')2及其临床应用前景[J].上海医学, 2012, 33(19):13-15.
[35]仇秋菊,宾文凯.马血清破伤风抗毒素与马破伤风免疫球蛋白F(ab')2过敏反应比较[J].蛇志, 2015, 27(3):263-265.
[36]Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 2006, 55(RR-3):1-34.
[37]Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel[J]. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 2006, 55(RR-17):1-37.
[38]Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-Advisory Committee on Immunization Practices (ACIP), 2012[J]. MMWR. Morbidity and mortality weekly report, 2012, 61(25):468-470.
[39]Quinn RH, Wedmore I, Johnson E, et al. Wilderness Medical Society Practice Guidelines for Basic Wound Management in the Austere Environment[J]. Wilderness Environ Med, 2014, 25(3):295-310.
[40]Tetanus:the green book, chapter 30[EB/OL].https://www.gov.uk/government/publications/tetanus-the-green-book-chapter-30. (last updated: 19 April 2013)
[41]Australian Technical Advisory Group on Immunisation(ATAGI). The Australian Immunisation Handbook 10th ed(2015 update)[M]. Canberra:Australian Government Department of Health, 2015:407-418.
[42]何庆,丛鲁红.创伤后破伤风免疫预防方案的比较分析[J]. 中华创伤杂志, 2007, 23(7): 555-557.
[43]王雪霏,郭树彬,魏学,等.人破伤风免疫球蛋白在预防破伤风使用中的问题及对策[J].中华急诊医学杂志, 2015, 24(5):573-575.
[44]Rhee P, Nunley MK, Demetriades D, et al. Tetanus and trauma:a review and recommendations[J]. J Trauma, 2005, 58(5):1082-1088.
[45]Verde F, Riboldi G, Zappa C, et al. An old woman with pressure ulcer,rigidity,and opisthotonus:never forget tetanus![J]. Lancet, 2014, 384(9961):2266.
[46]邬裕琼.肛周脓肿术后并发破伤风1例报告[J].广州中医药大学学报, 2005, 22(3):254-254.
[47]王海东,徐德征,杨含维.急性肠扭转坏死肠切除术后并发破伤风一例[J].新疆医科大学学报, 1987, 10(3):224.
[48]杨贵博,王传林.破伤风预防现状及常见误区[J].创伤外科杂志, 2014, 16(1):94-96.
[49]Hatamabadi HR, Abdalvand A, Safari S, et al. Tetanus Quick Stick as an applicable and cost-effective test in assessment of immunity status[J]. Am J Emerg Med, 2011, 29(7):717-720.
[50]N'Diaye DS, Schwarzinger M, Obach D, et al. Effectiveness and cost of quick diagnostic tests to determine tetanus immunity in patients with a wound in French emergency departments[J]. BMC Infect Dis, 2014, 14:603.
[51]Orsi GB, Modini C, Principe MA, et al. Assessment of tetanus immunity status by tetanus quick stick and anamnesis:a prospective double blind study[J]. Ann Ig, 2015, 27(2):467-474.
[52]Chithra A, Cariappa KM, Kamath AT, et al. Role of Rapid Tetanus Antibody Test in Accident and Emergency Department[J]. J Maxillofac Oral Surg, 2015, 14(3):784-788.
[53]李芬, 才战军, 孔令娜. 饮酒时间对破伤风抗毒素皮试结果的影响[J]. 中华现代护理杂志, 2011, 17(35):4381-4382.
[54]Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus:an evidence-based review[J]. Crit Care, 2014, 18(2):217.
[55]Thwaites CL, Yen LM.Tetanus.In Harrison’s Principles of Internal Medicine[M]. 18th edition.Edited by Longo DL, Fauci AS, Kasper DL, et al.New York: McGraw Hill Inc, 2011:1197-1200.
[56]Lisboa T, Ho YL, Henriques Filho GT, et al. Guidelines for the management of accidental tetanus in adult patients[J]. Rev Bras Ter Intensiva, 2011, 23(4):394-409.
[57]Okoromah CN, Lesi FE. Diazepam for treating tetanus[J]. Cochrane Database Syst Rev, 2004, 1, CD003954.
[58]Miya K, Shimojo N, Koyama Y, et al. Efficacy of concomitant use of dexmedetomidine and propofol in tetanus[J]. Am J Emerg Med, 2015, 33(12):1848.e3-4.
[59]Ozer.Cinar S, Isil CT. Dexmedetomidine in the management of severe tetanus[J]. Indian J Anaesth, 2014, 58(1):96-97.
[60]Girgin NK, Iscimen R, Gurbet A, et al. Dexmedetomidine sedation for the treatment of tetanus in the intensive care unit[J]. British J Anaesth, 2007, 99(4):599-600.
[61]Blake JA. The treatment of tetanus by magnesium sulphate[J]. Ann Surg, 1906, 44(3):367-373.
[62]Rodrigo C, Samarakoon L, Fernando S D, et al. A meta-analysis of magnesium for tetanus[J].Anaesthesia, 2012, 67(12):1370-1374.
[63]Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus:a randomised controlled trial[J]. Lancet, 2006, 368(9545):1436-1443.
[64]Boots RJ, Lipman J, O'Callaghan J, et al. The treatment of tetanus with intrathecal baclofen[J]. Anaesth Intensive Care, 2000, 28(4):438-442.
[65]Santos M L, Motamiranda A, Alvespereira A, et al. Intrathecal baclofen for the treatment of tetanus.[J]. Clinical Infectious Diseases, 2004, 38(3):321-328.
[66]Solsona M, Miro G, Yebenes JC, et al. Tetanus treated with continuous baclofen intrathecal perfusion[J]. Med Intensiva, 2007, 31(4):204-206.
[67]Cabrerizo Garcia JL, Homs Gimeno CA, Pacheco Arancibia G, et al. Treatment of tetanus with intrathecal baclofen[J]. An Med Interna, 2008, 25(7):372-373.
[68]Sugimoto M, Fukami S, Kayakiri H, et al. The beta-lactam antibiotics, penicillin-G and cefoselis have different mechanisms and sites of action at GABA(A) receptors[J]. Br J Pharmacol, 2002, 135(2):427-432.
[69]Ahmadsyah I, Salim A. Treatment of tetanus:an open study to compare the efficacy of procaine penicillin and metronidazole[J]. Br Med J(Clin Res Ed), 1985, 291(6496):648-650.
[70]Ganesh Kumar AV, Kothari VM, Krishnan A, et al. Benzathine penicillin,metronidazole and benzyl penicillin in the treatment of tetanus:a randomized, controlled trial[J]. Ann Trop Med Parasitol, 2004, 98(1):59-63.
[71]Farrar JJ, Yen JM, Cook T, et al. Tetanus[J].J Neurol Neurosurg Psychiatry, 2000, 69(3):292-301.[72]Abrutyn E, Berlin JA. Intrathecal therapy in tetanus, A meta-analysis[J]. JAMA, 1991, 266(16):2262-2267.
[73]Miranda-Filho Dde B, Ximenes RA, Barone AA, et al. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route[J]. BMJ, 2004, 328(7440):615.
[74]Kabura L, Ilibagiza D ,Menten J, et al. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus:a meta-analysis[J]. Trop Med Int Health, 2006, 11(7):1075-1081.
[75]中华医学会呼吸病学分会感染学组.中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018版)[J].中华结核和呼吸杂志, 2018, 41(4):255-280.